Jump to main content
Jump to site search

All chapters
Previous chapter Next chapter

CHAPTER 5

Designed Macrocyclic Kinase Inhibitors

Cancer continues to present as an increasing and serious global unmet medical need in today's aging population.1 Macrocyclic kinase inhibitors have reached advanced clinical testing and are making an impact in oncologic conditions including myelofibrosis, lymphomas and leukemias. Rheumatoid arthritis (RA) is also beginning to be impacted with the first macrocycle having entered Phase I clinical evaluation in healthy volunteers. Increasing reports of innovative macrocycles in preclinical research are appearing in the literature. Desirable, selective, multi-kinase inhibitory profiles against specific kinases known to be abrogated in cancer, RA, and other diseases have been achieved in a first generation series of clinical stage compact small molecule macrocyclic kinase inhibitors. Herein we discuss their design, synthesis, structure activity relationships and assessment of the latest clinical data in a range of oncologic conditions. Macrocyclic kinase inhibitors have the potential to offer new hope to patients and their families.

Publication details


Print publication date
16 Oct 2014
Copyright year
2015
Print ISBN
978-1-84973-701-2
PDF eISBN
978-1-78262-311-3
ePub eISBN
978-1-78262-316-8
From the book series:
Drug Discovery